

Medical Policy Bulletin

Title:

Intravenous (IV) Iron Preparations

Policy #:

MA08.150

The Company makes decisions on coverage based on the Centers for Medicare and Medicaid Services (CMS) regulations and guidance, benefit plan documents and contracts, and the member's medical history and condition. If CMS does not have a position addressing a service, the Company makes decisions based on Company Policy Bulletins. Benefits may vary based on contract, and individual member benefits must be verified. The Company determines medical necessity only if the benefit exists and no contract exclusions are applicable. Although the Medicare Advantage Policy Bulletin is consistent with Medicare's regulations and guidance, the Company's payment methodology may differ from Medicare.

When services can be administered in various settings, the Company reserves the right to reimburse only those services that are furnished in the most appropriate and cost-effective setting that is appropriate to the member's medical needs and condition. This decision is based on the member's current medical condition and any required monitoring or additional services that may coincide with the delivery of this service.

This Policy Bulletin document describes the status of CMS coverage, medical terminology, and/or benefit plan documents and contracts at the time the document was developed. This Policy Bulletin will be reviewed regularly and be updated as Medicare changes their regulations and guidance, scientific and medical literature becomes available, and/or the benefit plan documents and/or contracts are changed.

Policy

Coverage is subject to the terms, conditions, and limitations of the member's Evidence of Coverage.

The Company reserves the right to reimburse only those services that are furnished in the most appropriate and cost-effective setting that is appropriate to the member's medical needs and condition.

MEDICALLY NECESSARY

COMPANY-DESIGNATED PREFERRED PRODUCTS

Although there are many brands of intravenous (IV) iron products on the market for the treatment of iron deficiency (ID) or iron-deficiency anemia (IDA), there is no reliable evidence of the superiority of any one brand of IV iron product compared with other brands. The Company has designated the following as its preferred IV iron products for use in adult individuals aged 18 years and older who are treatment-naïve:

- Ferumoxytol (e.g., Feraheme®)
- Sodium ferric gluconate complex in sucrose (e.g., Ferrlecit®)
- Iron dextran (e.g., INFeD®)
- Iron sucrose (e.g., Venofer®)

Ferumoxytol (e.g., Feraheme), sodium ferric gluconate complex in sucrose (e.g., Ferrlecit), iron dextran (e.g., INFeD), and iron sucrose (e.g., Venofer) are less costly and at least as likely to produce equivalent therapeutic results as the non-preferred IV iron products, which include, but are not limited to, ferric carboxymaltose (Injectafer®) and ferric derisomaltose (Monoferric®).

NON-PREFERRED PRODUCTS

The Company has designated the following as its non-preferred IV iron products for use in adult individuals aged 18 years and older:

- Ferric carboxymaltose (Injectafer)
- Ferric derisomaltose (Monoferric)

For individuals who meet the medically necessary criteria below use of non-preferred IV iron products (which include, but are not limited to, ferric carboxymaltose [Injectafer], ferric derisomaltose [Monoferric]) is considered medically

necessary and, therefore, covered when the individual has a documented intolerance, contraindication, or nonresponse to at least two preferred IV iron preparations (i.e., ferumoxylol [e.g., Feraheme], sodium ferric gluconate complex in sucrose [e.g., Ferrlecit], iron dextran [e.g., INFeD], iron sucrose [e.g., Venofer]).

Management of Heart Failure

The use of ferric carboxymaltose (Injectafer) for the treatment of adult individuals with New York Heart Association class II/III heart failure is considered medically necessary and, therefore, covered without the need to try any preferred IV iron products to improve exercise capacity.

Management of Iron Deficiency (ID) or Iron Deficiency Anemia (IDA) Without Chronic Kidney Disease (CKD)

The use of a non-preferred IV iron product, for the treatment of ID or IDA without CKD, is considered medically necessary and, therefore, covered for adult individuals with **ALL** of the following:

- Individual has met the requirements listed in the COMPANY-DESIGNATED PREFERRED PRODUCTS and NON-PREFERRED PRODUCTS sections above
- Diagnosis of anemia based on hemoglobin (hgb) below normal levels for the individual's age and sex (if using to treat IDA)
- Ferritin level less than 30 ng/mL **OR** transferrin saturation (TSAT) less than 20 percent
- Normal kidney function as demonstrated by laboratory values (e.g., urine albumin, creatinine, glomerular filtration ratio [GFR])
- Documented intolerance, contraindication, or nonresponse to oral iron supplementation for at least 3 months

Management of Iron Deficiency (ID) or Iron Deficiency Anemia (IDA) With Chronic Kidney Disease (CKD)

The use of a non-preferred IV iron product, for the treatment of ID or IDA with CKD, is considered medically necessary and, therefore, covered for adult individuals with **ALL** of the following:

- Individual has met the requirements listed in the COMPANY-DESIGNATED PREFERRED PRODUCTS and NON-PREFERRED PRODUCTS sections above
- Diagnosis of anemia based on hgb below normal levels for individual's age and sex (if using to treat IDA)
- **ONE** of the following:
 - Ferritin level 100 ng/mL or less **AND** TSAT less than 20 percent in nondialysis individuals or those receiving peritoneal dialysis
 - Ferritin level 200 ng/mL or less **AND** TSAT less than 20 percent in individuals on hemodialysis
- CKD as demonstrated by abnormal laboratory values (e.g., urine albumin, creatinine, GFR)
- Documented intolerance, contraindication, or nonresponse to oral iron supplementation for at least 3 months

Management of Cancer- and Chemotherapy-Induced Anemia

The use of a non-preferred IV iron product, for the treatment of cancer- and chemotherapy-induced anemia, is considered medically necessary and, therefore covered for adult individuals who have met the requirements listed in the COMPANY-DESIGNATED PREFERRED PRODUCTS and NON-PREFERRED PRODUCTS sections above, and with **EITHER** of the following:

- For the treatment of **EITHER** of the following:
 - Absolute iron deficiency (ferritin <30 ng/mL and transferrin saturation <20 percent)
 - Possible functional iron deficiency (ferritin >500–800 ng/mL and transferrin saturation <50 percent) in selected individuals (with the goal of avoiding allogeneic transfusion)

- In combination with erythropoiesis-stimulating agents (ESAs) for the treatment of **EITHER** of the following:
 - Functional iron deficiency (ferritin 30–500 ng/mL and transferrin saturation <50 percent) in individuals receiving myelosuppressive chemotherapy without curative intent and ESAs
 - Absolute iron deficiency (ferritin <30 ng/mL and transferrin saturation <20 percent) in individuals who do not experience an increase in hemoglobin after 4 weeks of IV or oral iron supplementation

NOT MEDICALLY NECESSARY

For individuals receiving their first course of IV iron preparations, for use in adult individuals age 18 years and older, use of non-preferred ferric carboxymaltose (Injectafer) or ferric derisomaltose (Monoferric) to treat the specified indications (excluding the heart failure indication) is considered not medically necessary and, therefore, not covered because they are more costly than the preferred products that are at least as likely to produce equivalent therapeutic results for that individual's condition.

EXPERIMENTAL/INVESTIGATIONAL

All other uses for intravenous iron are considered experimental/investigational and, therefore, not covered unless the indication is supported as an accepted off-label use, as defined in the Company medical policy on off-label coverage for prescription drugs and biologics.

REQUIRED DOCUMENTATION

The individual's medical record must reflect the medical necessity for the care provided. These medical records may include, but are not limited to: records from the professional provider's office, hospital, nursing home, home health agencies, therapies, and test reports.

The Company may conduct reviews and audits of services to our members, regardless of the participation status of the provider. All documentation is to be available to the Company upon request. Failure to produce the requested information may result in a denial for the drug.

Guidelines

BLACK BOX WARNINGS

Refer to the specific manufacturer's prescribing information on ferumoxytol (Feraheme) and iron dextran (INFeD) for any applicable Black Box warnings.

BENEFIT APPLICATION

Subject to the terms and conditions of the applicable Evidence of Coverage, intravenous iron is covered under the medical benefits of the Company's Medicare Advantage products when the medical necessity criteria listed in this medical policy are met.

US FOOD AND DRUG ADMINISTRATION (FDA) STATUS

Ferric carboxymaltose (Injectafer) was approved by the FDA on July 25, 2013 for the treatment of iron deficiency anemia in adult individuals who have intolerance to or have unsatisfactory response to oral iron or individuals who have non-dialysis dependent chronic kidney disease (CKD). Supplemental approvals for ferric carboxymaltose (Injectafer) have since been issued by the FDA.

Ferric derisomaltose (Monoferric) was approved by the FDA on January 16, 2020 for the treatment of iron deficiency anemia in adult individuals who have intolerance to or have had unsatisfactory response to oral iron or individuals who have non-hemodialysis dependent chronic kidney disease.

Ferumoxytol (Feraheme) was approved by the FDA on June 30, 2009 for the treatment of iron deficiency anemia (IDA) in adult individuals with chronic kidney disease (CKD). Supplemental approvals for ferumoxytol (Feraheme) have since been issued by the FDA.

Iron dextran (INFeD) was approved by the FDA on August 12, 2009 for the treatment of individuals with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Supplemental approvals for iron dextran

(INFeD) have since been issued by the FDA.

Iron sucrose (Venofer) was approved by the FDA on November 6, 2000 for the treatment of IDA in individuals undergoing chronic hemodialysis who are receiving supplemental erythropoietin therapy. Supplemental approvals for iron sucrose (Venofer) have since been issued by the FDA.

Sodium ferric gluconate complex in sucrose (Ferrlecit) was approved by the FDA on February 18, 1999 for the treatment of iron deficiency in individuals undergoing chronic hemodialysis who are receiving supplemental erythropoietin therapy. Supplemental approvals for sodium ferric gluconate complex in sucrose (Ferrlecit) have since been issued by the FDA.

PEDIATRIC USE

The safety and effectiveness of ferric carboxymaltose (Injectafer) in pediatric individuals less than 1 year of age with iron deficiency anemia have not been established.

The safety and effectiveness of ferric derisomaltose (Monoferic) in pediatric individuals have not been established.

The safety and effectiveness of ferumoxytol (Feraheme) in pediatric individuals less than 18 years old have not been established.

The safety and effectiveness of iron dextran (INFeD) in infants under 4 months of age have not been established. Iron dextran (INFeD) is not recommended for use in infants under 4 months of age.

The safety and effectiveness of iron sucrose (Venofer) for iron replacement treatment in pediatric individuals with dialysis and non-dialysis-dependent chronic kidney disease (CKD) have not been established.

The safety and effectiveness of sodium ferric gluconate complex in sucrose (Ferrlecit) have been established in pediatric individuals 6 to 15 years old, but have not been established in pediatric individuals younger than 6 years old.

BILLING GUIDELINES

Inclusion of a code in this policy does not imply reimbursement. Eligibility, benefits, limitations, exclusions, precertification/referral requirements, provider contracts, and Company policies apply.

Description

Iron is absorbed from the gastrointestinal (GI) tract from food and stored in the liver in the form of ferritin. When needed by the body, the ferritin is released into the bone marrow to help make new red blood cells. When the red blood cells reach the end of their life cycle and undergo hemolysis, iron from those cells can be recycled and reused. If iron stores become depleted, either due to loss of blood, lack of adequate iron intake in the diet, or the lack of the body to absorb iron from the GI tract, iron-deficiency anemia (IDA) can occur. This can result in inadequate provision of oxygen to the body tissues and organs leading to multiple health issues. Although there can be other causes of anemia, IDA is the most common cause worldwide. The estimated prevalence of IDA in North America is 2.9 percent.

Common causes of IDA can include menstruation, pregnancy, breastfeeding, chronic kidney disease (CKD), major surgery, physical trauma, GI diseases (ulcerative colitis, Crohn's disease, celiac disease, peptic ulcer disease), GI malignancies, bariatric procedures, and vegetarian or vegan diets. There are multiple other less common causes of IDA as well. Efforts to identify and treat the cause(s) are necessary.

Blood tests are used to diagnose IDA. Results of laboratory tests will demonstrate the following: low hemoglobin (hgb), low mean cellular volume (MCV), low serum iron, low ferritin, low iron saturation, high transferrin, and high total iron-binding capacity (TIBC). When an individual is found to be anemic, as demonstrated by a low hgb, the next step is to look at the ferritin levels. There are different recommendations for the cut-off value for serum ferritin levels to define IDA proposed by different professional societies. The World Health Organization (WHO) recommends less than 12 ng/mL for healthy individuals under the age of 5 years, and less than 15 ng/mL for healthy individuals ages 5 years and above. For individuals with infection or inflammation, the levels increase to less than 30 ng/mL and less than 70 ng/mL for the same groups. The National Heart, Lung, and Blood Institute (NHLBI) recommend a cut-off level for ferritin at less than 10 ng/mL. The American Gastroenterological Association (AGA) recommends a cut-off level for ferritin at less than 45 ng/mL.

Once IDA has been identified, treatment can begin. Identifying the cause of the IDA can occur at the same time that the IDA is being treated. Treatment is usually begun with oral iron supplementation. If the individual is unable to tolerate oral iron supplementation, has a documented contraindication to oral iron supplementation, or has a documented nonresponse to oral iron supplementation, then erythropoiesis-stimulating agents (ESAs) and/or intravenous (IV) iron can be ordered. ESAs work by helping the bone marrow make more red blood cells (RBCs). Individuals who are on hemodialysis for end-stage renal disease (ESRD) can receive these medications while they are undergoing their dialysis treatments. If the anemia is severe enough that the individual has symptoms (e.g., fatigue, weakness, dizziness, lightheadedness), then the individual may require transfusions of blood products.

Ferric carboxymaltose (Injectafer) is a colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron.

Ferric derisomaltose (Monoferric) is a complex of iron (III) hydroxide and derisomaltose, an iron carbohydrate oligosaccharide that releases iron. Iron binds to transferrin for transport to erythroid precursor cells to be incorporated into hemoglobin.

Ferumoxytol (Feraheme) consists of a superparamagnetic iron oxide that is coated with a carbohydrate shell, which helps to isolate the bioactive iron from plasma components until the iron-carbohydrate complex enters the reticuloendothelial system macrophages of the liver, spleen, and bone marrow. The iron is released from the iron-carbohydrate complex within vesicles in the macrophages. Iron then either enters the intracellular storage iron pool (e.g., ferritin) or is transferred to plasma transferrin for transport to erythroid precursor cells for incorporation into hemoglobin.

Iron dextran (INFeD) is a complex of ferric hydroxide and dextran that releases iron into the circulation in order to replenish hemoglobin and depleted iron stores.

Iron sucrose (Venofer) is an aqueous complex of polynuclear iron (III) hydroxide in sucrose. Following intravenous administration, iron sucrose (Venofer) is dissociated into iron and sucrose and the iron is transported as a complex with transferrin to target cells including erythroid precursor cells. The iron in the precursor cells is incorporated into hemoglobin as the cells mature into red blood cells.

Sodium ferric gluconate complex in sucrose (Ferrlecit) is a stable macromolecular complex and is used to replete the body content of iron.

OFF-LABEL INDICATIONS

There may be additional indications contained in the Policy section of this document due to evaluation of criteria highlighted in the Company's off-label policy, and/or review of clinical guidelines issued by leading professional organizations and government entities.

References

Adkinson NF, Strauss WE, Macdougall IC, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial. *Am J Hematol*. 2018;93(5):683-690.

American Hospital Formulary Service (AHFS). Ferric carboxymaltose (Injectafer®). AHFS Drug Information 2024. [UpToDate Lexidrug Web site]. 03/11/2024. Available at: <https://online.lexi.com/lco/action/home> [via subscription only]. Accessed August 22, 2024.

American Hospital Formulary Service (AHFS). Ferric derisomaltose (Monoferric®). AHFS Drug Information 2024. [UpToDate Lexidrug Web site]. 08/02/2024. Available at: <https://online.lexi.com/lco/action/home> [via subscription only]. Accessed August 22, 2024.

American Hospital Formulary Service (AHFS). Ferumoxytol (Feraheme®). AHFS Drug Information 2024. [UpToDate Lexidrug Web site]. 03/11/2024. Available at: <https://online.lexi.com/lco/action/home> [via subscription only]. Accessed August 22, 2024.

American Hospital Formulary Service (AHFS). Iron dextran (INFeD®). AHFS Drug Information 2024. [UpToDate Lexidrug Web site]. 03/26/2024. Available at: <https://online.lexi.com/lco/action/home> [via subscription only]. Accessed August 22, 2024.

American Hospital Formulary Service (AHFS). Iron sucrose (Venofer®). AHFS Drug Information 2024. [UpToDate Lexidrug Web site]. 03/11/2024. Available at: <https://online.lexi.com/lco/action/home> [via subscription only]. Accessed August 22, 2024.

American Hospital Formulary Service (AHFS). Sodium ferric gluconate complex in sucrose (Ferrlecit®). AHFS Drug Information 2024. [UpToDate Lexidrug Web site]. 03/11/2024. Available at: <https://online.lexi.com/lco/action/home> [via subscription only]. Accessed August 22, 2024.

American Society of Hematology (ASH). Iron-deficiency anemia. [ASH Web site]. Available at: <https://www.hematology.org/education/patients/anemia/iron-deficiency>. Accessed August 22, 2024.

Auerbach M, DeLoughery TG. Causes and diagnosis of iron deficiency and iron deficiency anemia in adults. [UpToDate Web site]. 07/15/2024. Available at: [https://www.uptodate.com/contents/causes-and-diagnosis-of-iron-deficiency-and-iron-deficiency-anemia-in-adults?search=iron deficiency anemia&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2](https://www.uptodate.com/contents/causes-and-diagnosis-of-iron-deficiency-and-iron-deficiency-anemia-in-adults?search=iron%20deficiency%20anemia&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2) [via subscription only]. Accessed August 22, 2024.

Berns JS. Diagnosis of iron deficiency in chronic kidney disease. [UpToDate Web site]. 03/12/2024. Available at: [https://www.uptodate.com/contents/diagnosis-of-iron-deficiency-in-chronic-kidney-disease?search=diagnosis of iron deficiency anemia&topicRef=7150&source=see_link](https://www.uptodate.com/contents/diagnosis-of-iron-deficiency-in-chronic-kidney-disease?search=diagnosis%20of%20iron%20deficiency%20anemia&topicRef=7150&source=see_link) [via subscription only]. Accessed August 22, 2024.

Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD). NCD 110.10: intravenous iron therapy. Effective date: 10/01/2001. Available at: [NCD - Intravenous Iron Therapy \(110.10\)](#). Accessed August 22, 2024.

Centers for Medicare & Medicaid Services (CMS). Prior authorization and step therapy for part B drugs in Medicare Advantage. 08/07/2018. Available at: https://www.cms.gov/Medicare/Health-Plans/HealthPlansGenInfo/Downloads/MA_Step_Therapy_HPMS_Memo_8_7_2018.pdf. Accessed August 22, 2024.

Charytan C, Bernardo MV, Kock TA, et al. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. *Nephrol Dial Transplant*. 2013;28(4):953-964.

Elsevier's Clinical Pharmacology Compendium. Ferric carboxymaltose (Injectafer®). [Clinical Key Web site]. 03/06/2024. Available at: <https://www.clinicalkey.com/#!/> [via subscription only]. Accessed August 22, 2024.

Elsevier's Clinical Pharmacology Compendium. Ferric derisomaltose (Monoferric®). [Clinical Key Web site]. 08/05/2024. Available at: <https://www.clinicalkey.com/#!/> [via subscription only]. Accessed August 22, 2024.

Elsevier's Clinical Pharmacology Compendium. Ferumoxytol (Feraheme®). [Clinical Key Web site]. 01/11/2024. Available at: <https://www.clinicalkey.com/#!/> [via subscription only]. Accessed August 22, 2024.

Elsevier's Clinical Pharmacology Compendium. Iron dextran (INFeD®). [Clinical Key Web site]. 08/02/2024. Available at: <https://www.clinicalkey.com/#!/> [via subscription only]. Accessed August 22, 2024.

Elsevier's Clinical Pharmacology Compendium. Iron sucrose (Venofer®). [Clinical Key Web site]. 08/02/2024. Available at: <https://www.clinicalkey.com/#!/> [via subscription only]. Accessed August 22, 2024.

Elsevier's Clinical Pharmacology Compendium. Sodium ferric gluconate complex in sucrose (Ferrlecit®). [Clinical Key Web site]. 08/07/2024. Available at: <https://www.clinicalkey.com/#!/> [via subscription only]. Accessed August 22, 2024.

Ferric carboxymaltose (Injectafer®). 05/2023. Prescribing information. Available at: <https://daiichisankyo.us/prescribing-information-portlet/getDocument?product=IF&inline=true>. Accessed August 22, 2024.

Fishbane S, Bolton WK, Winkelmayer WC, et al. Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. *Clin Nephrol*. 2012;78(3):181-188.

Goldstein SL, Morris D, Warady BA. Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial. *Am J Kidney Dis*. 2013;61(4):588-597.

Hetzel D, Strauss WE, Bernard K, et al. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. *Am J Hematol*. 2014;89(6):646-650.

Ko, CW, Siddique SM, Patel A, et al. AGA clinical practice guidelines on the gastrointestinal evaluation of iron deficiency anemia. *Gastroenterology*. 2020;159(3):1085-1094.

Macdougall IC, Strauss WE, Dahl NV, et al. Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. the FACT randomized controlled trial. *Clin Nephrol*. 2019;91(4):237-245.

Macdougall IC, Strauss WE, McLaughlin J, et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. *Clin J Am Soc Nephrol*. 2014;9(4):705-712.

Merative Micromedex® DRUGDEX® (electronic version). Ferric carboxymaltose (Injectafer®), ferric derisomaltose (Monoferric®), iron dextran (INFeD®), iron sucrose (Venofer®), sodium ferric gluconate complex in sucrose (Ferrlecit®). [Micromedex Web site]. 07/01/2024. Available at: <https://www.micromedexsolutions.com/micromedex2/librarian> [via subscription only]. Accessed August 22, 2024.

Merative Micromedex® DRUGDEX® (electronic version). Ferumoxytol (Feraheme®). [Micromedex Web site]. 10/05/2023. Available at: <https://www.micromedexsolutions.com/micromedex2/librarian> [via subscription only]. Accessed August 22, 2024.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology®. Hematopoietic Growth Factors V3.2024. [NCCN Web site]. 01/30/2024. Available from: https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf. [via subscription only]. Accessed August 22, 2024.

National Comprehensive Cancer Network (NCCN). NCCN Drugs & Biologics Compendium®. [NCCN Web site]. Ferric carboxymaltose (Injectafer®), ferric derisomaltose (Monoferric®), ferumoxytol (Feraheme®), iron dextran (INFeD®), iron sucrose (Venofer®), sodium ferric gluconate complex in sucrose (Ferrlecit®). Available at: https://www.nccn.org/professionals/drug_compendium/content/ [via subscription only]. Accessed August 22, 2024.

National Heart, Lung, and Blood Institute (NHLBI). Iron-deficiency anemia. [NHLBI Web site]. 03/24/2022. Available at: <https://www.nhlbi.nih.gov/health/anemia/iron-deficiency-anemia>. Accessed August 22, 2024.

Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. *Transfusion*. 2014;54(2):306-315.

Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. *Nephrol Dial Transplant*. 2014;29(4):833-842.

Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. *Eur Heart J*. 2015;36(11):657-668.

Provenzano R, Schiller B, Rao M, et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. *Clin J Am Soc Nephrol*. 2009;4(2):386-393.

Short MW, Domagalski JE. Iron deficiency anemia: evaluation and management. *Am Fam Physician*. 2013;87(2):98-104.

Singh H, Reed J, Noble S, et al. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. *Clin J Am Soc Nephrol*. 2006;1(3):475-482.

Strauss WE, Dahl NV, Lau G, Allen FL. Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients with varying renal function and iron deficiency anemia. BMC Hematol. 2016;16:20.

UpToDate® Lexidrug™. Ferric carboxymaltose (Injectafer®). [UpToDate Lexidrug Web site]. 08/22/2024. Available at: <https://online.lexi.com/lco/action/home> [via subscription only]. Accessed August 22, 2024.

UpToDate® Lexidrug™. Ferric derisomaltose (Monoferic®). [UpToDate Lexidrug Web site]. 08/22/2024. Available at: <https://online.lexi.com/lco/action/home> [via subscription only]. Accessed August 22, 2024.

UpToDate® Lexidrug™. Ferumoxytol (Feraheme®). [UpToDate Lexidrug Web site]. 08/22/2024. Available at: <https://online.lexi.com/lco/action/home> [via subscription only]. Accessed August 22, 2024.

UpToDate® Lexidrug™. Iron dextran (INFeD®). [UpToDate Lexidrug Web site]. 08/22/2024. Available at: <https://online.lexi.com/lco/action/home> [via subscription only]. Accessed August 22, 2024.

UpToDate® Lexidrug™. Iron sucrose (Venofer®). [UpToDate Lexidrug Web site]. 08/22/2024. Available at: <https://online.lexi.com/lco/action/home> [via subscription only]. Accessed August 22, 2024.

UpToDate® Lexidrug™. Sodium ferric gluconate complex in sucrose (Ferrlecit®). [UpToDate Lexidrug Web site]. 08/22/2024. Available at: <https://online.lexi.com/lco/action/home> [via subscription only]. Accessed August 22, 2024.

US Food and Drug Administration (FDA). Center for Drug Evaluation and Research. Ferric carboxymaltose (Injectafer®). Prescribing information. [FDA Web site]. 05/31/2023. Available at: <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>. Accessed August 22, 2024.

US Food and Drug Administration (FDA). Center for Drug Evaluation and Research. Ferric derisomaltose (Monoferic®). Prescribing information. [FDA Web site]. 08/01/2024. Available at: <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>. Accessed August 22, 2024.

US Food and Drug Administration (FDA). Center for Drug Evaluation and Research. Ferumoxytol (Feraheme®). Prescribing information. [FDA Web site]. 06/16/2022. Available at: <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>. Accessed August 22, 2024.

US Food and Drug Administration (FDA). Center for Drug Evaluation and Research. Iron dextran (INFeD®). Prescribing information. [FDA Web site]. 08/01/2024. Available at: <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>. Accessed August 22, 2024.

US Food and Drug Administration (FDA). Center for Drug Evaluation and Research. Iron sucrose (Venofer®). Prescribing information. [FDA Web site]. 08/01/2024. Available at: <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>. Accessed August 22, 2024.

US Food and Drug Administration (FDA). Center for Drug Evaluation and Research. Sodium ferric gluconate complex in sucrose (Ferrlecit®). Prescribing information. [FDA Web site]. 03/16/2022. Available at: <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>. Accessed August 22, 2024.

Vadhan-Raj S, Strauss WE, Ford D, et al. Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Am J Hematol. 2014;89(1):7-12.

Van Wyck DB, Roppolo M, Martinez CO, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68(6):2846-2856.

World Health Organization (WHO). WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. 2020. Available at: <https://iris.who.int/handle/10665/331505>. Accessed August 22, 2024.

Inclusion of a code in this table does not imply reimbursement. Eligibility, benefits, limitations, exclusions, precertification/referral requirements, provider contracts, and Company policies apply.

The codes listed below are updated on a regular basis, in accordance with nationally accepted coding guidelines. Therefore, this policy applies to any and all future applicable coding changes, revisions, or updates.

In order to ensure optimal reimbursement, all health care services, devices, and pharmaceuticals should be reported using the billing codes and modifiers that most accurately represent the services rendered, unless otherwise directed by the Company.

The Coding Table lists any CPT, ICD-10, and HCPCS billing codes related only to the specific policy in which they appear.

CPT Procedure Code Number(s)

N/A

ICD - 10 Procedure Code Number(s)

N/A

ICD - 10 Diagnosis Code Number(s)

D50.9 Iron deficiency anemia, unspecified

D63.0 Anemia in neoplastic disease

D63.1 Anemia in chronic kidney disease

E61.1 Iron deficiency

I50.89 Other heart failure

I50.9 Heart failure, unspecified

HCPCS Level II Code Number(s)

J1437 Injection, ferric derisomaltose, 10 mg

J1439 Injection, ferric carboxymaltose, 1 mg

J1750 Injection, iron dextran, 50 mg

J1756 Injection, iron sucrose, 1 mg

J2916 Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg

Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-ESRD use)

Q0139 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for ESRD on dialysis)

Revenue Code Number(s)

N/A

Policy History

Revisions From MA08.150:

12/15/2025	This policy will become effective 12/15/2025.
------------	---

	This new policy has been developed to communicate the Company's coverage criteria for intravenous (IV) iron preparations.
--	---

Version Effective Date:
12/15/2025
Version Issued Date:
12/15/2025
Version Reissued Date:
N/A